Complex regional pain syndrome (CRPS) is a pain syndrome of the extremities that can result in severe disability. CRPS is diagnosed using diagnostic Budapest criteria based on signs and symptoms, whereby sensory, autonomic, vasomotor, motor and trophic disturbances are assessed. Many pathophysiological mechanisms are proposed in the development and disease course of CRPS, starting with exaggerated inflammation and resulting in vascular deregulation, central sensitisation and cortical reorganisation.
In the Netherlands, approximately 4,300 patients develop CRPS each year, whereby females are affected three times more than males and the highest incidence is found between the age of 61 and 70 years. 
Diagnosing Complex Regional Pain Syndrome
The diagnosis of CRPS is based on clinically observed signs and symptoms reported by the patient. Additional laboratory or radiological assessments provide insufficient basis for diagnosing CRPS, but should be used to exclude other pathologies (such as an unresolved fracture or active infection). 4 Several sets of diagnostic criteria have been proposed over the past decades, some of which are still being used concurrently. The criteria of Veldman et al. 5 are based on the identification of a limited amount of signs and symptoms, which are present predominantly in the acute phase of CRPS. The International Association for the Study of Pain (IASP)-Orlando criteria 6 allow for the diagnosis to be made almost exclusively based on anamnestic information and appear to be more sensitive than the Veldman et al. criteria. 7 More specific criteria have been developed by Bruehl and Harden 8 requiring both anamnestic and observed information regarding sensory, vasomotor, motor, sudomotor and motortrophic disturbances. An adapted version of the latter criteria set has been validated internationally, resulting in a diagnostic tool that combines good specificity with excellent sensitivity for diagnosing CRPS: the Budapest criteria (see Table 1 ). 9 These criteria have recently been adopted by the IASP as the international standard for diagnosing CRPS.
To maximise the comparability of studies of CRPS and ensure agreement between clinicians involved in diagnosing and treating CRPS, a uniform and internationally accepted criteria set such as the Budapest criteria is necessary. Uniform diagnosis and assessment of CRPS could be further improved by identification of disease markers of CRPS Type 1 (CRPS-1) and development of objective assessment tools.
Neurogenic Inflammation
A trauma can easily result in micro-injury of small nerve fibres, which in turn triggers the release of neuropeptides, such as substance P (SP) and calcitonin gene-related peptide (CGRP) in the periphery. 10 17 A role for increased oxidative stress is also supported by the observation of elevated levels of oxidative markers in the serum and saliva of patients with CRPS-1. 18 Furthermore, leukocyte accumulation in the affected extremity has been observed in patients with CRPS, probably resulting from increased vascular permeability owing to oxidative stress. 19 Tissue hypoxia, as shown by the poor oxygenation of skin in patients with CRPS, 20 lends further support to this observation. The efficacy of free radical scavengers, such as dimethylsulfoxide and N-Acetylcysteine, 21, 22 in the treatment of CRPS-1 and the preventive effect of vitamin C after fractures 23, 24 in the development of this disease provide indirect evidence for the oxidative stress hypothesis.
Autonomic Disturbances
Hyperactivity of the sympathetic nervous system has long been thought to be the primary pathophysiological mechanism of CRPS-1, resulting in increased vasoconstriction, increased sweating and trophic disturbances. However, studies have shown lower levels of sympathetic neurotransmitters in the affected limb 25-27 compared with the unaffected limb, indicating decreased sympathetic activity.
Presumably, increased sensitivity of α-adrenergic receptors, probably resulting from reduction of sympathetic neural traffic, would explain this phenomenon. 28 The extent in which autonomic disturbances are observed can differ depending on the stage of the disease course. 29 
Vascular Dysfunction
An alternative hypothesis for the vasomotor instability observed in patients with CRPS is based on endothelial dysfunction resulting in hypoxia, a decrease in nitric oxide (NO) synthase and an increase in endothelin-1. 30 This dysfunction leads to clinical features, such as a cold affected extremity and discolouration (pale, blue skin), and other features of CRPS associated with oxygen deprivation.
Neuronal Excitation and Central Sensitisation
Clinical features displayed in CRPS, such as allodynia, hyperalgesia and wind-up, have been related to the process of central sensitisation. 31 This process is triggered by the release of SP, CGRP and glutamate after tissue damage, which in turn activate the normally dormant N-methyl-D-aspartic acid (NMDA) receptor. 32 Elevated levels of glutamate found in the serum and cerebrospinal fluid of patients with CRPS are suggestive of the involvement of NMDA receptor responses. 33 Central sensitisation might also influence the Complex Regional Pain Syndrome -Diagnosis, Treatment and Future Perspectives with CRPS, such as dystonia, tremor or myoclonia. 34 
Cortical Reorganisation
Pain and sensory disturbances in CRPS often spread from the location of the initial trauma to a larger area, sometimes even to another extremity, which might indicate plastic changes of the central nervous system owing to neurogenic inflammation. 35 In patients with CRPS, reorganisation of the primary somatosensory cortex (S1) has been observed, which correlated with the amount of pain and hyperalgesia experienced by the patients. 36, 37 Cerebral representation and motor processing in the brain are also reported to be disturbed, possibly leading to movement disorders in CRPS-1 and distorted visualised representation of the affected limb.
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Psychological Factors
Psychological disturbances have often been proposed to be involved in complex conditions, such as chronic pain and CRPS.
However, little evidence has emerged to support this hypothesis.
No relation has been found between psychological dysfunction, disease-related fear or personality and the development of CRPS. [42] [43] [44] One study reports that stressful life events are more common in patients with CRPS than in controls, 45 
Vasodilatory Medication
For treatment of patients with CRPS and vasomotor disturbances, α-1 adrenergic blockers, phenoxybenzamine and terazosin, or calcium influx blockers, such as nifedipine, can be considered. 4, 55, 71 No reduction in temperature asymmetry was found for NO-regulating medication (e.g. tadalafil or isosorbide dinitrate) in primary cold CRPS, although tadalafil is superior to placebo in reducing pain for this subgroup. 72, 73 Likewise, intravenous administration of ketanserine is reported to reduce pain in CRPS.
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Spasmolytics
Movement disorders in CRPS-1, such as dystonia, myoclonia and tremor, might benefit from treatment with baclofen or benzodiazepines. 4, 50, 63 Treatment with anti-cholinergics has not shown to be beneficial for CRPS-related movement disorders over a longer period of time.
34 4. There is no other diagnosis that better explains the signs and symptoms
Physical Therapy
An important modality for treatment of CRPS is physical therapy directed at increasing control over pain and improving skills. 57, 75 Motor imagery and mirror therapy have been proven effective, both of which are applied to counter disturbed cortical motor processing, resulting in improvement of pain and function. 41, 76, 77 Transcutaneous electrical nerve stimulation (TENS) might be beneficial for treatment of pain in a subgroup of patients and might therefore be a suitable adjunctive non-invasive therapy. However, evidence for the latter is limited. 4 
Invasive Treatment
Spinal cord stimulation with an implantable generator can be considered for patients with chronic CRPS; however, the high incidence and severity of complications following spinal cord stimulation warrant careful patient selection. 78 Spinal cord stimulation should not be considered in early stages of CRPS. 79 Studies of intrathecal administration of baclofen show that patients with CRPS dystonia can experience marked improvement in pain and disability levels, paralleled by improvement in quality of life. 80, 81 However, as with other intrathecal approaches, complications can be severe and, therefore, should be limited to patients who are refractory to conventional therapy and be conducted by physicians with ample experience with intrathecal devices. 81 
Psychological Treatment
Although studies with regard to psychological interventions for CRPS are limited, treatment by a psychologist can be considered in cases where disease burden is high or there is a discrepancy between noted pain behaviour and observed signs and symptoms of CRPS. 63 Graded exposure is a promising therapy to reduce fear of pain and to regain functionality of the affected extremity. 49 Complex Regional Pain Syndrome -Diagnosis, Treatment and Future Perspectives Repetitive transcranial magnetic stimulation (rTMS), whereby the motor cortex is stimulated to treat neuropathic pain, has been shown to provide short-term pain relief in patients with CRPS-1. 90 However, issues related to placebo response and ways to prolong its efficacy need to be addressed. 
